Indoleacetic Acid Derivatives for Cough Relief With Fewer Side Effects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antitussive and antiasthmatic drugs have significant side effects and limitations, such as narrow safe ranges, cardiac issues, severe reactions, and slow onset of action, necessitating the development of a more effective and safer treatment for cough and bronchial asthma.
Innovation Solution
Development of indoleacetic acid derivatives, including specific compounds and their pharmaceutically acceptable salts, which are synthesized through a series of chemical reactions and formulated into various pharmaceutical compositions for oral, injectable, and other administration forms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If central cough medicines (methadone, codeine, morphine) are used, then antitussive effect is improved, but side effects (nausea, constipation, lethargy, addiction) worsen
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of indoleacetic acid through systematic variation of substituents at different positions (R1-R6 groups). This structural parameter optimization aims to enhance antitussive activity while reducing harmful side effects, resolving the contradiction between efficacy and safety.
Solution Approach 2:
The patent employs composite material principles by creating complex indoleacetic acid derivatives with multiple substituted groups (halogen, alkyl, alkoxy, amino, cyano, nitro groups at various positions). These composite molecular structures combine different functional groups to achieve both strong antitussive effect and reduced side effects.
2Reliability
If theophyllines are used, then bronchodilator effect is improved, but safety range worsens (narrow safe range requiring blood concentration monitoring)
Solution Approach 1:
The patent modifies molecular parameters of indoleacetic acid derivatives to achieve potent bronchodilator activity with improved safety profile. By optimizing substituent patterns and molecular configuration, the compounds aim to provide therapeutic effect at safe concentration levels without requiring intensive monitoring.
3Reliability
If non-selective β2 receptor agonist is used, then antiasthmatic effect is improved, but side effects (cardiac responses, tachycardia, palpitation) worsen
Solution Approach 1:
The patent applies local quality principle by designing indoleacetic acid derivatives with specific substituent patterns that target bronchial β2 receptors selectively. The molecular structure is optimized to have high affinity for airway smooth muscle receptors while minimizing interaction with cardiac β2 receptors, thereby achieving strong antiasthmatic effect with reduced cardiac side effects.
4Reliability
If selective β2 receptor drugs (salbutamol) are used, then antiasthmatic effect is improved, but side effects (abnormal heartbeat, increased heart rate, dizziness) worsen
Solution Approach 1:
The patent optimizes molecular parameters of indoleacetic acid derivatives to enhance selectivity for bronchial receptors over cardiac receptors. By adjusting substituent types, positions, and configurations, the compounds achieve improved therapeutic index with reduced cardiac adverse effects.
5Reliability
If glucocorticoid (dexamethasone) is used, then anti-inflammatory antiasthmatic effect is improved, but long-term side effects (osteoporosis, severe withdrawal reactions) worsen
Solution Approach 1:
The patent modifies the chemical structure of indoleacetic acid derivatives to achieve potent anti-inflammatory activity with improved safety for long-term use. By optimizing molecular parameters and substituent patterns, the compounds aim to provide effective anti-inflammatory protection while minimizing adverse effects such as osteoporosis and withdrawal reactions.
6Reliability
If antiallergic antiasthmatic drugs (ketotifen, sodium cromoglycate) are used, then anti-allergic effect is improved, but onset of action worsens (slow onset, cannot be used in acute attacks)
Solution Approach 1:
The patent optimizes molecular parameters of indoleacetic acid derivatives to achieve both potent anti-allergic activity and rapid onset of action. By adjusting substituent patterns and molecular configuration, the compounds aim to provide fast-acting relief suitable for acute asthma attacks while maintaining preventive efficacy.
Data Source
AI summary
The present invention relates to an indoleacetic acid derivative and a preparation method and pharmaceutical use thereof. In particular, the present invention relates to a compound shown in general formula (I), a preparation method thereof, a pharmaceutical composition comprising the same, and a use thereof as a cough suppressant in treating a disease such as a cough. The definition of each substituent in the general formula (I) is the same as the definition in the specification.